# Risk factors for major cardiovascular adverse events and the effects of sacubitril/valsartan in patients with acute myocardial infarction after Percutaneous Coronary Intervention

## TL;DR

This study finds that sacubitril/valsartan reduces major cardiovascular events and improves heart function in patients after heart attack and PCI.

## Contribution

The study identifies new risk factors for MACEs and demonstrates the benefits of sacubitril/valsartan in post-AMI PCI patients.

## Key findings

- SV reduced MACEs incidence from 56.67% to 30.78% compared to non-SV group.
- SV improved blood lipid levels and cardiac function metrics significantly.
- Independent risk factors for MACEs include age ≥70, smoking, and delayed PCI timing.

## Abstract

To investigate the risk factors for major cardiovascular adverse events (MACEs) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), and observe the effect of sacubitril/valsartan (SV) on these events.

This was a retrospective study. One hundred and twenty-five patients with AMI undergoing PCI admitted to The First Affiliated Hospital of Yangtze University from January 2022 to August 2024 were included and divided into MACEs group(n=54) and non-MACEs group(n=71) according to whether MACEs occurred one week after PCI. Univariate/multivariate logistics regression analysis of risk factors for MACEs. Patients were divided into SV group(n=65) and non-SV group(n=60) according to whether taking SV, adverse events, blood lipids, hemorheology, and cardiac function were compared using Chi-square or t-test.

The incidence of MACEs was 43.20% (54/125). Logistics regression analysis showed that an age of ≥70 years, smoking history, hyperlipidemia, anemia, hypertension grade≥2, and time from onset to balloon dilation ≥7 hours were independent risk factors for MACEs. The incidence of MACEs was 30.78% in SV group, lower than non-SV group (56.67%) (χ2=8.528, P=0.003). After 6 months of treatment, the levels of TG, TC, and LDL-C were significantly decreased, and the level of HDL-C was significantly increased in SV group compared with non-SV group (P<0.05). The improvement in whole blood high/low shear viscosity, plasma viscosity, the level of fibrinogen,LVEDD, LVEBD, and LVEF was better in SV group than non-SV group(P<0.05).

Use of SV can improve blood lipids, hemorheology, and cardiac function, and reduce the incidence of post-PCI MACEs in these patients.